{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T01:40:04Z","timestamp":1749087604844,"version":"3.41.0"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Doc Ophthalmol"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s10633-025-10023-4","type":"journal-article","created":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T12:34:45Z","timestamp":1747744485000},"page":"199-200","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Response: Aflibercept for the treatment of pigmentary retinopathy in Kearns-Sayre Syndrome?"],"prefix":"10.1007","volume":"150","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8431-9040","authenticated-orcid":false,"given":"Vannessa","family":"Leung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John R.","family":"Grigg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,20]]},"reference":[{"issue":"9434","key":"10023_CR1","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/S0140-6736(04)16851-7","volume":"364","author":"PF Chinnery","year":"2004","unstructured":"Chinnery PF, DiMauro S, Shanske S, Schon EA, et al (2004) Risk of developing a mitochondrial DNA deletion disorder. The Lancet 364(9434):592\u2013596","journal-title":"The Lancet"},{"issue":"1","key":"10023_CR2","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s10633-024-09999-2","volume":"150","author":"V Leung","year":"2025","unstructured":"Leung V, Wong JG, Grigg JR (2025) Anti-VEGF therapy for proliferative diabetic retinopathy in Kearns-Sayre syndrome. Doc Ophthalmol 150(1):41\u201346","journal-title":"Doc Ophthalmol"},{"issue":"Suppl 1","key":"10023_CR3","doi-asserted-by":"publisher","first-page":"i11","DOI":"10.1136\/bjophthalmol-2014-305302","volume":"98","author":"D Malik","year":"2014","unstructured":"Malik D, Tarek M, del Carpio JC, Ramirez C, Boyer D, Kenney MC, Kuppermann BD (2014) Safety profiles of anti-VEGF drugs: bevacizumab, ranibizumab, aflibercept and ziv-aflibercept on human retinal pigment epithelium cells in culture. Br J Ophthalmol 98(Suppl 1):i11\u2013i16","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"10023_CR4","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1200\/JCO.2005.05.098","volume":"23","author":"KD Miller","year":"2005","unstructured":"Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, Dickler M, Overmoyer BA, Reimann JD, Sing AP (2005) Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23(4):792\u2013799","journal-title":"J Clin Oncol"},{"issue":"3","key":"10023_CR5","doi-asserted-by":"publisher","first-page":"533","DOI":"10.3390\/ijms18030533","volume":"18","author":"W Shen","year":"2017","unstructured":"Shen W, Yau B, Lee S-R, Zhu L, Yam M, Gillies MC (2017) Effects of Ranibizumab and Aflibercept on human m\u00fcller cells and photoreceptors under stress conditions. Int J Mol Sci 18(3):533","journal-title":"Int J Mol Sci"},{"issue":"8","key":"10023_CR6","doi-asserted-by":"publisher","first-page":"e631","DOI":"10.1111\/aos.12745","volume":"93","author":"S-J Sheu","year":"2015","unstructured":"Sheu S-J, Chao Y-M, Liu N-C, Chan JYH (2015) Differential effects of bevacizumab, ranibizumab and aflibercept on cell viability, phagocytosis and mitochondrial bioenergetics of retinal pigment epithelial cell. Acta Ophthalmol 93(8):e631\u2013e643","journal-title":"Acta Ophthalmol"},{"issue":"9","key":"10023_CR7","doi-asserted-by":"publisher","first-page":"H1453","DOI":"10.1152\/ajpheart.00554.2015","volume":"309","author":"ZV Varga","year":"2015","unstructured":"Varga ZV, Ferdinandy P, Liaudet L, Pacher P (2015) Drug-induced mitochondrial dysfunction and cardiotoxicity. Am J Physiol-Heart Circ Physiol 309(9):H1453\u2013H1467","journal-title":"Am J Physiol-Heart Circ Physiol"}],"container-title":["Documenta Ophthalmologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10633-025-10023-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10633-025-10023-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10633-025-10023-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T01:23:39Z","timestamp":1749086619000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10633-025-10023-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,20]]},"references-count":7,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10023"],"URL":"https:\/\/doi.org\/10.1007\/s10633-025-10023-4","relation":{},"ISSN":["0012-4486","1573-2622"],"issn-type":[{"type":"print","value":"0012-4486"},{"type":"electronic","value":"1573-2622"}],"subject":[],"published":{"date-parts":[[2025,5,20]]},"assertion":[{"value":"10 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Nil.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}